Seeking Alpha

Day Trader001's  Instablog

Day Trader001
Send Message
Retired from US Airways, Day Trading is a great, but with these markets Swing Trading is more to the norm and quite profitable. Advocate for the Horizon House in Indianapolis. The Horizon House is the only Day Shelter for the homeless in the city and does wonderful work assisting people in... More
My company:
Horizon House....Homeless Day Shelter
View Day Trader001's Instablogs on:
  • Heavy Hitters Coming To Vivus, Gearing Up For Qnexa Approval!
    VIVUS Announced Expansion of Management Team

    MOUNTAIN VIEW, Calif., March 27, 2012 (GLOBE NEWSWIRE)

    VVUS a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced the addition of several key employees and expansion of the senior management team in anticipation of the commercialization of Qnexa®, if approved. New hires in the commercial group include Chris Thompson as national sales director and Alfred Tenuto as senior director of market access.
    VIVUS has also added Santosh T. Varghese, M.D., as vice president of medical affairs. Barbara Troupin, M.D., MBA, has been promoted to vice president, scientific communication & risk management, and Timothy E. Morris will continue in his role as chief financial officer and will assume responsibility for business development as senior vice president global corporate development and finance. VIVUS has also expanded executive management in its clinical group with the addition of Roman V. Dvorak, M.D., Ph.D, who will serve as senior director, clinical development.

    "The addition of experienced professionals in the commercial, medical affairs, and clinical groups will be invaluable as we prepare for the commercialization of Qnexa, if approved. Chris, Alfred and Santosh represent over 70 years of successful pharmaceutical commercial experience and are a welcome addition to our team," commented Leland Wilson, chief executive officer of VIVUS.

    "Barbara will continue to work with key opinion leaders and will head up the risk management responsibilities for Qnexa, Tim will lead our partnering efforts worldwide, and Roman will assist with the design and implementation of a post-approval Qnexa cardiovascular outcomes study."

    Chris Thompson joins VIVUS as the national sales director after a successful 23-year career with Amgen, most recently as the vice president, sales of the Bone Health Business Unit. In this role, Mr. Thompson recruited and managed a team of over 545 employees, including 500 endocrine and primary care sales representatives. During his career at Amgen, Mr. Thompson rose through the ranks from a field sales representative to executive management positions. In addition, he has sales and sales management experience with Baxter International and Johnson & Johnson.

    Alfred Tenuto joins VIVUS as the senior director of market access after a successful 13-year career with Eli Lilly & Company, most recently as director of trade. In this role, Mr. Tenuto was responsible for the distribution network and relationships with wholesalers and specialty pharmacies. At VIVUS, he will manage the Qnexa distribution network and be responsible for Federal and State public policy and reimbursement with private third party payors. In addition, he has pharmaceutical market access, pharmacy and national accounts experience with ALZA.

    Dr. Varghese joins VIVUS as vice president medical affairs. Dr. Varghese comes from Elan Corporation, where he was responsible for the global and U.S. medical affairs bio-neurology therapeutic group for Tysabri. Prior to Elan, he built and led medical affairs teams responsible for large brands, such as Allegra and Nasacort at Aventis/Sanofi-Aventis; Clarinex/Claritin, Nasonex, Integrilin, Zetia, Vytorin, and other compounds within Schering-Plough/Merck. At VIVUS, he will establish the medical affairs group for Qnexa and will provide scientific and medical brand strategy to the commercial team. In addition, he will supervise and provide direction to field based teams and assume responsibility for safety and interaction with the FDA.

    Dr. Troupin has been promoted to the newly created position of vice president of scientific communication and risk management. Dr. Troupin has been vice president of scientific communication and risk management since February 2012. Prior to that, she held senior director roles in medical affairs and in clinical development at VIVUS initially joining the company in April 2006. Before joining VIVUS (VVUS:$20.65,00$-0.37,00-1.76%) , Dr. Troupin was the medical director for Profil Institute for Clinical Research in San Diego, a niche Phase 1 site focused on complex clinical trials in diabetes and obesity. Prior to that she was the medical director for Radiant Research in San Diego for five years and was the principal investigator on more than 150 cardiovascular and metabolic clinical studies. In her new role, Dr. Troupin will supervise development of publications and presentations, advise in the development of Scientific Symposia and Advisory Boards, and establish and support communications with medical and scientific key opinion leaders and advocates. In addition, she will take responsibility for the implementation of the Risk Evaluation and Mitigation Strategies (REMS) for Qnexa.

    In addition to his current role as senior vice president finance and chief financial officer, Mr. Morris assumes responsibility for global corporate development, including partnering efforts for Qnexa.

    Tags: VVUS
    Mar 27 10:24 AM | Link | Comment!
  • Upcoming IPO’S.

    Upcoming IPO's.

    (NASDAQ:BV) Baxaarvoice $8-10 "retailers review platform"

    (NYSE:PRLB) Proto Labs $13-15 "molded custom parts for prototyping"

    (NASDAQ:CERE) Ceres $16-17 sometime this month "renewable bioenergy feedstock's"

    (NASDAQ:ARGS) Argos Therapeutics $13-15 sometime this month "biotech"

    (GCT) Semiconductor $7-9 next week "4G chip supplier"

    (NYSE:YELP) Yelp $12-14 next week "business reviews website"
    Feb 20 4:28 PM | Link | Comment!
  • ISIS stock rising with positive developments & investment.

    There are positive developments at ISIS! “Stock rising”

    Isis Pharma Results Show Treatment With Isis-Ttrrx Produced Dose-Dependent Statistically Significant Reductions Of Greater Than 80 % In Transthyretin Protein >ISIS

    (DJ Real-time News – 8:12 AM ET 01/05/2012)

    -------------------------------------------------------------------------------------------------

     ISIS Reports Phase 1 Data Demonstrating ISIS-TTRRx Produces Significant Reductions In TTR Protein >ISIS

    (DJ Real-time News – 8:02 AM ET 01/05/2012) 


    "" Lets make MONEY ""

    Tags: ISIS
    Jan 08 2:58 PM | Link | Comment!
Full index of posts »
Latest Followers

StockTalks

  • 5 Things $AAL 's Management Wants You to Know. Interesting article found on (Motley Fool) $DAL $UAL $LUV http://bit.ly/1pqAimc
    6 days ago
  • $PG's due for "another" dive back to $79. Great company with the bouncing share...
    7 days ago
  • Delta Air Lines, Inc. $DAL Leads Pack of Soaring Airline Stocks. $AAL $UAL $LUV http://bit.ly/1wiCSPP
    7 days ago
More »

Latest Comments


Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.